Literature DB >> 27201719

Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute.

S Rule1, J Briones2, R Smith3, Oklota C Theodore4, C A Ngoh3, S Osborne3, E Capochiani5, M Rummel6.   

Abstract

Entities:  

Year:  2014        PMID： 27201719     DOI： 10.1016/j.jval.2014.08.1719

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  5 in total

Review 1.  A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma.

Authors:  D MacDonald; T Crosbie; A Christofides; W Assaily; J Wiernikowski
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

2.  Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.

Authors:  Pieternella Lugtenburg; Irit Avivi; Henriette Berenschot; Osman Ilhan; Jean Pierre Marolleau; Arnon Nagler; Antonio Rueda; Monica Tani; Mehmet Turgut; Stuart Osborne; Rodney Smith; Michael Pfreundschuh
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

Review 3.  Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria.

Authors:  Helen Doll; Ufuk Coşkun; Chris Hartford; Ioannis Tomazos
Journal:  J Patient Rep Outcomes       Date:  2021-06-21

Review 4.  Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Authors:  Andrew Davies; Claude Berge; Axel Boehnke; Anjum Dadabhoy; Pieternella Lugtenburg; Simon Rule; Mathias Rummel; Christine McIntyre; Rodney Smith; Xavier Badoux
Journal:  Adv Ther       Date:  2017-10-05       Impact factor: 3.845

5.  Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.

Authors:  Simon Rule; Wolney Gois Barreto; Javier Briones; Angelo M Carella; Olivier Casasnovas; Chris Pocock; Clemens-Martin Wendtner; Francesco Zaja; Susan Robson; Lachlan MacGregor; Roger R Tschopp; Sonja Nick; Martin Dreyling
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.